BridgeBio Pharma Inc
NASDAQ:BBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BridgeBio Pharma Inc
NASDAQ:BBIO
|
US |
|
Finwise Bancorp
NASDAQ:FINW
|
US |
|
S
|
Shop Apotheke Europe NV
XETRA:SAE
|
NL |
|
A
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
ZA |
|
Reynolds Consumer Products Inc
NASDAQ:REYN
|
US |
|
Changzhou Zhongying Science & Technology Co Ltd
SZSE:300936
|
CN |
BridgeBio Pharma Inc
BridgeBio Pharma Inc. stands as a compelling figure in the biotechnology sector, driven by its mission to address and rectify genetic diseases at their root. Formed with the belief that breakthrough medicines for genetic disorders could be developed with unprecedented speed and precision, the company focuses on identifying clinically validated genetic pathways. By collaborating with leading researchers and utilizing sophisticated drug development platforms, BridgeBio seeks to rapidly translate genetic insights into medical innovations. The company's distinct approach concentrates on single-gene disorders across various therapeutic areas including oncology, cardiology, dermatology, and neurology.
The financial workings of BridgeBio Pharma revolve around its robust pipeline of targeted therapies. Essentially, its revenue model is anchored in developing investigational therapies that hold the potential for lucrative partnerships and licensing deals with larger pharmaceutical entities. As these therapies progress through clinical stages, their valuation—and hence the potential for revenue—significantly increases. BridgeBio also leverages a strategy of creating subsidiary companies for each drug in its pipeline, promoting both focus and accountability. This organizational structure enables efficient capital allocation and innovation while also opening up opportunities for public market offerings and strategic exits, thereby driving the financial engine of BridgeBio.
BridgeBio Pharma Inc. stands as a compelling figure in the biotechnology sector, driven by its mission to address and rectify genetic diseases at their root. Formed with the belief that breakthrough medicines for genetic disorders could be developed with unprecedented speed and precision, the company focuses on identifying clinically validated genetic pathways. By collaborating with leading researchers and utilizing sophisticated drug development platforms, BridgeBio seeks to rapidly translate genetic insights into medical innovations. The company's distinct approach concentrates on single-gene disorders across various therapeutic areas including oncology, cardiology, dermatology, and neurology.
The financial workings of BridgeBio Pharma revolve around its robust pipeline of targeted therapies. Essentially, its revenue model is anchored in developing investigational therapies that hold the potential for lucrative partnerships and licensing deals with larger pharmaceutical entities. As these therapies progress through clinical stages, their valuation—and hence the potential for revenue—significantly increases. BridgeBio also leverages a strategy of creating subsidiary companies for each drug in its pipeline, promoting both focus and accountability. This organizational structure enables efficient capital allocation and innovation while also opening up opportunities for public market offerings and strategic exits, thereby driving the financial engine of BridgeBio.
Revenue Growth: BridgeBio reported strong revenue growth, with Q4 total revenue at $154.2 million (up from $5.9 million last year) and full-year 2025 revenue at $502.1 million, driven primarily by Attruby.
Attruby Momentum: Attruby net product revenue reached $146 million in Q4 and $362.4 million for the year, with notable acceleration in new patient starts and increasing market share.
Pipeline Progress: The company marked a major inflection point with three successful Phase III results for encaleret (ADH1), BBP-418 (LGMD2I), and infigratinib (achondroplasia), setting up multiple late-stage launches.
Profitability Outlook: Management anticipates transitioning from cash burn to cash generation by late 2027, projecting over $600 million in profit by 2028.
ATTR Franchise Strength: Despite investor concerns about tafamidis intellectual property, management remains confident in Attruby's best-in-class clinical profile and ongoing strong uptake.
Cash Position: The company ended 2025 with $587.5 million in cash and recently raised $632.5 million through convertible notes, supporting future launches and growth.
Disciplined Spending: Operating expenses increased to support launches, but cash burn is expected to remain steady and decline further as revenue builds.
